Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBIT (2016 - 2025)

Historic EBIT for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $40.8 million.

  • Arrowhead Pharmaceuticals' EBIT rose 12528.25% to $40.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $300.6 million, marking a year-over-year increase of 14801.8%. This contributed to the annual value of $98.3 million for FY2025, which is 11636.15% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported EBIT of $40.8 million as of Q4 2025, which was up 12528.25% from $44.1 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' EBIT registered a high of $381.2 million during Q1 2025, and its lowest value of -$176.1 million during Q2 2024.
  • Its 5-year average for EBIT is -$48.5 million, with a median of -$68.9 million in 2021.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' EBIT crashed by 36199.73% in 2024, and later soared by 40208.33% in 2025.
  • Arrowhead Pharmaceuticals' EBIT (Quarter) stood at -$63.3 million in 2021, then surged by 33.46% to -$42.1 million in 2022, then tumbled by 224.07% to -$136.5 million in 2023, then dropped by 18.21% to -$161.4 million in 2024, then skyrocketed by 125.28% to $40.8 million in 2025.
  • Its EBIT was $40.8 million in Q4 2025, compared to $44.1 million in Q3 2025 and -$165.5 million in Q2 2025.